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Denis Nash11, Philippa J Easterbrook5, Paula Braitstein2, Beverly S Musick2, Jeffrey N Martin1,
Constantin T Yiannoutsos2 and Kara Wools-Kaloustian2

Abstract
Background: East Africa has experienced a rapid expansion in access to antiretroviral therapy (ART) for HIVinfected patients. Regionally representative socio-demographic, laboratory and clinical characteristics of patients
accessing ART over time and across sites have not been well described.
Methods: We conducted a cross-sectional analysis of characteristics of HIV-infected adults initiating ART between
2002 and 2009 in Kenya, Uganda and Tanzania and in the International Epidemiologic Databases to Evaluate AIDS
Consortium. Characteristics associated with advanced disease (defined as either a CD4 cell count level of less than
50 cells/mm3 or a WHO Stage 4 condition) at the time of ART initiation and use of stavudine (D4T) or nevirapine
(NVP) were identified using a log-link Poisson model with robust standard errors.
Results: Among 48, 658 patients (69% from Kenya, 22% from Uganda and 9% from Tanzania) accessing ART at 30
clinic sites, the median age at the time of ART initiation was 37 years (IQR: 31-43) and 65% were women. Pretherapy CD4 counts rose from 87 cells/mm3 (IQR: 26-161) in 2002-03 to 154 cells/mm3 (IQR: 71-233) in 2008-09 (p
< 0.001). Accessing ART at advanced disease peaked at 35% in 2005-06 and fell to 27% in 2008-09. D4T use in the
initial regimen fell from a peak of 88% in 2004-05 to 59% in 2008-09, and a greater extent of decline was observed
in Uganda than in Kenya and Tanzania. Self-pay for ART peaked at 18% in 2003, but fell to less than 1% by 2005. In
multivariable analyses, accessing ART at advanced immunosuppression was associated with male sex, women
without a history of treatment for prevention of mother to child transmission (both as compared with women
with such a history) and younger age after adjusting for year of ART initiation and country of residence. Receipt of
D4T in the initial regimen was associated with female sex, earlier year of ART initiation, higher WHO stage, and
lower CD4 levels at ART initiation and the absence of co-prevalent tuberculosis.
Conclusions: Public health ART services in east Africa have improved over time, but the fraction of patients
accessing ART with advanced immunosuppression is still high, men consistently access ART with more advanced
disease, and D4T continues to be common in most settings. Strategies to facilitate access to ART, overcome
barriers among men and reduce D4T use are needed.

* Correspondence: genge@php.ucsf.edu
1
Department of Medicine, San Francisco General Hospital, University of
California at San Francisco, 995 Potrero Avenue, San Francisco, USA
Full list of author information is available at the end of the article
© 2011 Geng et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.

Geng et al. Journal of the International AIDS Society 2011, 14:46
http://www.jiasociety.org/content/14/1/46

Background
An unprecedented global effort to provide antiretroviral
therapy (ART) to HIV-infected patients in resource-limited settings is underway. Led by the Global Fund to
Fight AIDS, Tuberculosis and Malaria, established in
2003, and the US President’s Emergency Fund for AIDS
Relief (PEPFAR), founded in 2004, US$50 billion had
been invested in global HIV/AIDS care, treatment and
prevention by 2009 [1]. As a result, 5 million HIVinfected persons in resource-limited settings have
started ART, and the World Health Organization
(WHO) estimates that in sub-Saharan Africa, 1.2 million
lives and 2.3 million life-years have been saved [2].
In east Africa, ART coverage based on initiation using
previous WHO criteria of CD4 counts of less than 200
cells/mm3 or 200-350 cells/mm3 with select conditions
has risen from less than 5% in 2002 to 65% in Kenya,
53% in Uganda and 44% in Tanzania by 2009 [3]. Access
to ART has also had a measureable impact on the economic and social dimensions of life in Africa by increasing labour capacity [4], maintaining educators [5],
increasing survival of children [6] and even raising educational attainment among children in households
affected by HIV [7]. Finally, the scale up has proven that
large-scale access to complex, potentially toxic, life-long
ART can be achieved in resource-limited settings - a
task that some experts considered implausible not long
ago [8].
Despite indisputable evidence of successes, more
information about the characteristics of patients starting
ART in “real-world settings” - and how those characteristics are changing over time - is needed to characterize
“gaps” in access to ART in east Africa. Trends in the
CD4 levels and WHO stage at the time of ART initiation can reveal the extent to which care is reaching
patients before advanced disease and the attendant high
risk of early mortality due to concurrent opportunistic
infections [9,10]. Demographic characterization of
patients starting ART over time may yield information
about socio-behavioural groups who face barriers to
care [11].
From a health systems perspective, examining the
changing characteristics of care, such as the fraction of
patients who self-pay for ART and the travel time from
home to clinic, over time can provide an understanding
of structural obstacles to care [12,13]. Finally, characterizing trends in access to ART services must also include
a consideration of the specific medications that are
being used. Nevirapine (NVP) was chosen as the nonnucleoside reverse transcriptase inhibitor (NNRTI) of
choice despite higher toxicity than efavirenz because of
substantially lower costs. The global roll out initially
relied heavily on stavudine (D4T), a relatively toxic drug
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which is being phased out; monitoring changes in the
use of D4T in first-line regimens over time is needed to
demonstrate progress [14].
To date, however, no reports contain enough data on
enough patients over enough time to provide a regionally representative picture of patients starting ART in
east Africa. The East Africa International Epidemiologic
Databases to Evaluate AIDS (EA-IeDEA) is a consortium
of clinic-based cohorts in Kenya, Uganda and Tanzania
that captures data from “real-world” settings in diverse
environments. Using data from 2002-2009, we describe
the epidemiologic characteristics of patients accessing
ART during this phase of the scale up in east Africa.

Methods
Patients

The EA-IeDEA is a cohort of patients from clinical care
sites in Uganda, Kenya and Tanzania. IeDEA seeks to
harmonize data from HIV care and treatment sites in
order to evaluate the effectiveness of the ART roll out
using data collected in representative “real-world settings” (i.e., in high-volume clinics providing care without
access to routine HIV RNA monitoring, staffed and
stocked by national ministries of health, or where an
implementing partner is implementing the “public
health approach”[15]).
In Kenya, participating programmes include the United States Agency for International Development-Academic Model Providing Access to Healthcare (USAIDAMPATH), the Family AIDS Care and Education Services based in Nyanza Province and Nyanza Provincial
Hospital. In Uganda, affiliated sites include the Infectious Diseases Institute and Mulago Hospital, the Nsambya Hospital in Kampala and the Immune Suppression
Syndrome Clinic in Mbarara, which is located in the
rural southwest part of the country. Contributing sites
in Tanzania include the Tumbi Regional Hospital in
Kibaha, the Ocean Road Cancer Institute in Dar es Salaam and the Morogoro Regional Hospital in Morogoro.
We evaluated data from all adult, treatment-naïve
patients starting ART between 2002 and 2009; patients
who were exposed to ART for prevention of mother to
child transmission (PMTCT) were included. The exact
date of database closure differed by clinic site and ranged from 31 March 2008 to 19 May 2009.
Measurements

Socio-demographic, clinical, medication and laboratory
data were collected in the course of routine clinical care
by providers on standardized forms specific to each of
the sites. Information collected on paper charts is manually entered into electronic databases by data entry
clerks. Prospective data quality control mechanisms to
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optimize accuracy and reduce missing data are a part of
data collection at all IeDEA sites and all employ one or
more of the following procedures: data entry range
restrictions; sampling of charts to identify missing and
erroneous data; and reconciliation of errors and missing
information with clinicians and primary records. At
every site, period audits are conducted by the regional
data centre.
We defined the pre-therapy CD4 value as the last CD4
determination within six months of ART initiation. The
pre-therapy WHO stage (which was routinely determined at all sites) was defined as the maximum WHO
stage documented for the patient before ART initiation.
“Programme” is defined by a single administrative unit
and “site” is defined by a single physical location for
ART services. For example, a programme (e.g., USAIDAMPATH) may have multiple sites (e.g., Eldoret, Burnt
Forest and Kitale). Tuberculosis (TB) was considered
present if either an active TB diagnosis was present at
ART initiation or if the patient was receiving anti-TB
therapy at the time of ART initiation. Continuous variables were discretized according to convention (CD4
count cut offs were made at 50, 100 and 200 cells/mm3)
or were split into quartiles (as in the case of age). The
joint effect of sex and history of PMTCT was handled
as a nominal categorical variable with levels equal to: (1)
women with no history of PMTCT; (2) men; and (3)
women with a history of PMTCT.
Analysis

We conducted cross-sectional analyses of socio-demographic, clinical and laboratory characteristics of patients
at the time they accessed ART, stratified by calendar
year of ART initiation, sex and across country to evaluate temporal and regional trends. Because of the large
number of comparisons (for example, of differences in a
given patient characteristic across strata of time and
country) we used graphical representation of the data
whenever possible. Statistical comparisons of continuous
variables across categorical groups were conducted with
analyses of variance (ANOVA) or linear regression. We
conducted single predictor and multivariable analyses to
identify factors associated with: (1) advanced immunesuppression (defined as a patient with either a CD4 level
of less than 50 cells/mm3 or WHO Stage 4 condition) at
the time of ART initiation; (2) receipt of D4T in the
first-line regimen; or (3) receipt of nevirapine (NVP) in
the first-line regimen.
In the subset of patients where data were available, we
examined factors associated with self-pay using logistic
regression. Predictor selection for multivariable models
was driven by substantive knowledge, as well as the
desire to include both individual-level predictors (e.g.,
age and sex) and ecological predictors (e.g., year of ART
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initiation, country and programme) to create “multilevel” models and to reduce confounding [16,17]. To
obtain more interpretable risk ratios, we used a log-link
Poisson model, with robust standard errors to avoid the
resulting misspecification of the model standard errors
and to account for clustering by site [18]. All analyses
were conducted in Stata version 11 (Stata Corporation,
College Station, TX). This study was reviewed and
approved by institutional review bodies of all participating sites and universities.

Results
In total, 48, 658 adult patients from 35 clinic sites and
from 10 programmes were included in this analysis. The
median number of patients at each clinic site was 788
(IQR: 342 to 1816) and in each programme was 1283
(range: 292-32, 221). Of the total patients, 33, 680 (69%)
were from Kenya, 10, 859 (22%) were from Uganda, and
4119 (9%) were from Tanzania. Of 35 sites, 28 were in
Kenya, four in Uganda and three in Tanzania. Overall,
1118 (2%) patients started ART in 2002-03, 12, 875
(27%) in 2004-05, 24, 811 (51%) in 2006-07, and 9854
(20%) in 2008-09 (Figure 1).
Socio-demographic characteristics

The median age at the time of ART initiation was 37
years (IQR: 31-43). When stratified by country, patients
in Uganda were slightly younger overall with a median
age of 36 years (IQR: 31-41) compared with those in
Kenya (median 37 years, IQR: 31-44) and in Tanzania
(median 38 years, IQR: 32-45). Overall, men who started
ART were older than women, with the average difference most pronounced in Tanzania (5.0 years, 95% CI:
4.4-5.7) compared with Uganda (4.2 years, 95% CI: 3.84.5) or Kenya (4.2 years, 95% CI: 4.0-4.4). The majority
of patients (65%) were women. Over time, men comprised a decreasing fraction of new patients accessing
ART in Kenya, dropping from 41% in 2002-03 to 34% in
2008-09 (p < 0.01), but the fraction of men accessing
care in Uganda and Tanzania did not change markedly.
Clinical characteristics

Overall, across time, 85% of patients had a pre-therapy
“baseline” CD4 determination, and the median was 122
cells/mm3 (IQR: 52 to 193). When stratified by country,
calendar time and sex, several trends are apparent. First,
the median pre-therapy CD4 counts rose over time
from 87 cells/mm 3 (IQR: 26-161) in 2002-03 to 105
cells/mm 3 (IQR: 38-179) in 2004-05, 121 cells/mm 3
(IQR: 54- 189) in 2006-07 and 154 cells/mm3 (IQR: 71233) in 2008-09 (p < 0.001). Second, the pre-therapy
CD4 counts summarized over all time points were on
average higher in women at 130 cells/mm3 (IQR: 59198) than in men at 107 cells/mm3 (IQR: 40-181) (p <
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Figure 1 The number of patients starting ART in the East Africa IeDEA Consortium each month, stratified by country.

0.001). Third, the rise is most marked among women in
Kenya and least among men in Tanzania (Figure 2).
Overall, 95% of patients had pre-therapy WHO stage
documented: of those, 16% were Stage 1, 21% were
Stage 2, 46% were Stage 3 and 17% were Stage 4. The
fraction of patients with WHO Stage 4 disease at the
time of accessing ART was lower in Kenya (12%) than
in Uganda (28%) and Tanzania (27%) (p < 0.001). The
percentage of patients with WHO Stage 4 conditions
declined significantly in Kenya from 20% in 2002-03 to
12% in 2008-09 (p for trend < 0.001), but rose in
Uganda from 33% to 36% (p for trend = 0.02) in the
same period. No change was seen in Tanzania (p for
trend = 0.21) (Figure 2). Presentation with advanced disease (i.e., a CD4 count < 50 cells/mm3 or WHO Stage 4)
in 2002-03 was 26%, 35% in 2004-05, 31% in 2006-07
and 27% in 2008-09.
Multivariable analyses found male sex (compared with
women with no history of PMTCT exposure), calendar
year, residence in Uganda and Tanzania and self-pay
were associated with accessing ART at advanced disease.
In contrast, women with a history of treatment for
PMTCT (compared with women with no history of

treatment for PMTCT) and older age were associated
with decreased risk of advanced disease at the time of
accessing ART (Table 1).
ART medication use

Among initial regimens which were available in 96% of
patients, stavudine (D4T) was the most common
nucleoside reverse-transcriptase inhibitor component
during the period of study: overall, 76% of patients
started ART regimens that contained D4T. The proportion of patients starting regimens with D4T actually
rose between 2002-03 (78%) and 2004-05 (88%), but
then fell in 2006-2007 (76%) and in 2008-2009 (59%).
In Kenya, D4T use fell consistently from 97% in 200203 to 68% in 2008-09 (p for trend < 0.001). In Uganda,
the fraction of initial regimens containing D4T rose
between 2002-03 and 2004-05 from 6% to 63%, but subsequently fell to 44% in 2006-07 and to 8% in 2008-09
(p for trend < 0.001). Of note, in Uganda during the
self-pay era, tenofovir was common, which disappeared
during the early days of the free ART era and more
recently has re-emerged: by 2008-09, 8% of patients
starting ART used tenofovir-based regimens. In
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Figure 2 Level of immunosuppression as measured by CD4 level and WHO stage at the time of ART initiation in the East Africa IeDEA
Consortium, stratified by time, country and (for CD4 levels) sex. Pre-therapy CD4 value is missing in 7283/48, 658 (15%). WHO stage is
missing in 2648/48, 658 (5%).

Tanzania, the reduction of D4T use has been less apparent: in 2004-05, 98% of initial regimens contained D4T
and in 2008-09, the fraction fell to 93% (p for trend <
0.001) (Figure 3a). In a multivariable model, higher
WHO stage was associated with a higher chance of D4T
use in the first regimen, whereas male sex, later calendar
time, residence in Uganda, higher CD4 cell count and
TB were associated with reduced use of D4T (Table 2).

For the NNRTI component of the initial regimens,
overall NVP was used in 80% of the regimens. The proportion of NVP-containing regimens fell from 83% in
2002-03 to 74% in 2008-09 (p for trend < 0.001). In
Kenya, the decrease in NVP use fell from 91% in 200203 to 81% in 2008-09. In Uganda, NVP use rose from
53% in 2002-03 to 72% in 2004-05 as free ART programmes scaled up, but then subsequently fell to 46% in

Table 1 Characteristics associated with advanced disease (defined as either a CD4 level ≤ 50 cells/mm3 or a WHO
Stage 4 condition) at the time of ART initiation using a log-link Poisson model with robust standard errors.
Factor

Number (%)
(n = 48, 658)

Prevalence ratio

95% confidence interval

P value

Sex*
Women without a history of PMTCT

29, 939

Ref.

Men

17, 173

1.33

1.26-1.41

< 0.001

Women with a history of PMTCT

1440

0.59

0.36-0.95

0.03

0.92

0.86-0.99

0.03

Calendar year of ART initiation, (per 2 years)
Country of residence
Kenya
Uganda

33, 680
10, 859

Ref.
1.28

1.04-1.57

0.04

Tanzania

4119

1.38

1.00-1.92

0.05

Age at ART initiation (years)
Quartile 1 (18-31)

13, 152

Ref.

Quartile 2 (32-37)

12, 766

0.98

0.82-1.04

0.44

Quartile 3 (38-43)

10, 662

0.97

0.89-1.05

0.40

Quartile 4 (44-88)

12, 078

0.85

0.79-0.91

< 0.001

46, 479

Ref.

574

1.41

1.24-1.59

< 0.001

Self-pay+
No
Yes

Each factor is adjusted for all other factors in the table (N = 48, 658)
* Missing in 106 of 48, 658 (0.2%)
+ Missing in 1605 (3.3%)
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Figure 3 Composition of non-lamivudine component of nucleoside reverse transcriptase inhibitor and non-nucleoside reverse
transcriptase inhibitor in the initial ART regimen among HIV-infected patients in the East Africa IeDEA Consortium, stratified by time
and country. First regimen is missing in 1879/48, 658 (4%).

2008-09 (p for trend < 0.001). In Tanzania, although
NVP use has decreased steadily, the overall fraction of
NVP use remained high: in 2002-03, 99% used NVP and
in 2008-09, the figure was 91% (Figure 3b). In

multivariable analysis, year of ART initiation and pretherapy CD4 count levels between 50 cells/mm 3 and
200 cells/mm3 were associated with NVP use, whereas
older age, male sex, higher WHO stage and TB

Table 2 Factors associated with the use of D4T in the first ART regimen in multivariable analysis using log-link
Poisson model with robust standard errors.
Factor

Number (%)
(n = 48, 658)

Risk ratio

95% Confidence interval

P value

Male sex*

17, 173

0.97

0.95-0.99

< 0.001

0.81

0.73-0.89

< 0.001

Year of ART initiation (per 2 years)
Country of residence
Kenya
Uganda

33, 680
10, 859

ref
0.49

0.33-0.72

< 0.001

Tanzania

4119

1.14

1.09-1.21

< 0.001

Quartile 1 (18-31)

13, 152

ref

Quartile 2 (32-37)

12, 766

1.00

0.99-1.02

0.58

Quartile 3 (38-43)

10, 662

1.00

0.99-1.03

0.52

Quartile 4 (44-88)

12, 078

0.99

0.97-1.02

0.56

Stage 1

7263

ref

Stage 2

9808

1.01

0.98-1.05

0.52

Stage 3

21, 291

1.06

1.02-1.11

< 0.01

Stage 4

7648

1.10

1.02-1.07

0.01

≤ 50 cells/mm3

10, 148

ref

51-100 cells/mm3
101-200 cells/mm3

7377
14, 528

0.97
0.87

0.89-1.06
0.81-0.94

0.27
0.09

> 200 cells/mm3

16, 605

0.86

0.80-0.93

0.02

0.94

0.90-0.98

< 0.01

Age at ART initiation (years)

+

WHO stage

Pre-therapy CD4 level

±

Presence of tuberculosis
Each factor is adjusted for all other factors in the table.
* Missing in 106 (0.2%)
+ Missing in 2648 (5.4%)
± Missing in 7283 (15.0%)
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diagnosis were associated with a reduced probability of
NVP use (Table 3).

than men (30%), (p < 0.001). By 2008-09, however, the
proportion was equivalent at 14%.

System of care

Discussion
This analysis, including nearly 50, 000 patients, over
eight years and covering a network of 30 sites in three
countries, suggests that in addition to rapid expansion,
the roll out of ART services for HIV-infected patients in
east Africa is improving in effectiveness. First, we documented that the median CD4 count at the time of ART
initiation in the east Africa region has increased substantially from 87 cells/mm 3 in 2002-03 to 185 cells/
mm 3 in 2008-09. Second, we found improvements in
the pharmaco-epidemiology of the roll out over time
with reductions in more toxic regimens: the use of D4T
in the first regimen fell from a peak of 88% to 58% in
2008-09, and the fraction of patients starting NVP-based
regimens decreased as more regimens made use if EFV
instead, even after taking into account changing trends
in sex of patients starting ART over time.
Third, the fraction of patients who had longer travelling times to a clinic declined by 50% in the programme
from which we had these data available, and this likely

Of 46, 479 patients with known information about payment for ART, 574 (1.2%) paid for ART. The fraction of
patients who paid peaked at 18% in 2003 and then
quickly fell to 12% in 2004, less than 1% in 2005 and
zero after 2005. Before 2006, when self-pay was completely phased out, men were more likely to pay for ART
than women (OR = 1.5, 95% CI: 1.2-1.74).
Travel time from home to clinic was available for
patients attending one programme in Kenya. Within this
group over all time periods, 27% of patients required
less than 30 minutes to travel to a clinic, 32% 31-60
minutes, 24% one to two hours, and 17% more than two
hours to get to a clinic. Overall, the fraction of patients
requiring more than two hours to access a clinic fell
over time from 28% in 2002-03 to 15% 2008-09. This
corresponds with a period when the number of clinic
sites in the programme increased from 15 to 23. During
the earliest time period, a smaller proportion of women
required more than two hours to get to a clinic (26%)

Table 3 Factors associated with the use of NVP in the first ART regimen using a log-link Poisson model with robust
standard errors.
Factor

Risk ratio

95% Confidence interval

P value

Male sex*

0.95

0.93-0.97

< 0.01

Calendar year of ART initiation (per 2 years)

0.94

0.89-0.99

0.03

Kenya
Uganda

ref
0.71

0.60-0.84

< 0.01

Tanzania

1.06

1.01-1.12

0.01

Country

Age at ART initiation (years)
Quartile 1 (18-31)

Ref.

Quartile 2 (32-37)

0.98

0.96-1.00

0.04

Quartile 3 (38-43)

0.97

0.95-1.00

0.04

Quartile 4 (44-88)

0.98

0.96-1.01

0.14

+

WHO stage at ART initiation
Stage 1

Ref.

Stage 2

1.02

0.99-1.05

0.09

Stage 3

0.98

0.96-1.01

0.46

Stage 4

0.91

0.70-0.86

< 0.01

1.02-1.08
1.00-1.13

< 0.01
0.02

Pre-therapy CD4 level

±

≤ 50 cells/mm3

Ref.

51-100 cells/mm3
101-200 cells/mm3

1.04
1.07

> 200 cells/mm3
Presence of tuberculosis
Each factor is adjusted for all other factors in the table.
* Missing in 106 (0.2%)
+ Missing in 2648 (5.4%)
± Missing in 7283 (15.0%)

1.03

0.99-1.07

0.14

0.72

0.70-0.75

< 0.01
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reflects the ongoing process of decentralization of ART
services, a key element of improving access to ART services. Lastly, our analysis underlines that, after 2005
when the Global Fund and PEPFAR began supporting
large-scale ART programmes, self-pay for ART, which
has been shown to be associated with poor outcomes in
Africa [19], essentially disappeared.
This analysis, which covers a large span of both time
(indeed, capturing data before the rapid Global Fundand PEPFAR-funded rise in ART availability in 2004-05)
and geographic regions, also presents the opportunity to
identify “gaps” in access to ART in east Africa. Existing
literature has suggested that more patients with
advanced disease at ART centres are men [20]. One
explanation is that many asymptomatic women with
high CD4 counts are detected when screened during
pregnancy and referred to ART centres.
Although we also found male sex to be associated
with advanced disease at presentation (defined as either
WHO Stage 4 or a CD4 count of ≤ 50 cells/mm3), we
also found that a history of PMTCT did not explain all
of this association. Men were 50% more likely to access
ART with advanced disease compared with women
without a history of PMTCT. But women without a history of PMTCT were nearly twice as likely to access
ART with advanced disease compared with women with
a history of PMTCT. Because most women tested during pregnancy receive some form of PMTCT, it appears
that socio-behavioural characteristics of men in east
Africa confer additional risk of having advanced disease
that is not completely explained by public health services targeting pregnant women. Further evaluation of
the causal reasons for the association between late disease presentation and male sex among patients accessing ART is required.
Although the magnitude of the differences were not
large, patients in Uganda and Tanzania in this analysis
were more likely to start ART with advanced disease as
compared with Kenya after adjustment for socio-demographic factors and calendar time. This is likely
explained by the fact that the Tanzanian scale up of
ART services occurred slightly later and coverage has
only recently begun to catch up with - a history that is
consistent with a programme seeing more advanced disease at ART initiation.
In Uganda, the risk of presentation with more
advanced disease is driven by a larger fraction of
patients with a WHO Stage 4 condition despite
approximately equal CD4 cell count levels. This association may be due to differential clinical assignment
of WHO stage when definitive diagnoses cannot always
be made. Further study, in cohorts where definitive
diagnoses are available, are needed to exclude the possibility that Ugandan patients have a higher disease
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burden even after accounting for CD4 count levels.
Overall, when compared with recent reports from
southern Africa, the demographics in our patients in
east Africa are similar (i.e., proportion of women and
age). The median CD4 count at ART initiation, however, is slightly higher at 122/mm 3 in our analysis as
compared with 103/mm 3 in South Africa during a
similar period. This likely reflects the higher burden of
disease in the epidemic population in South Africa
[21]. Furthermore, the CD4 count at ART initiation in
our study during 2008-09 period was 154 cells/mm 3 ,
which is not far from contemporaneous figures of 187
cells/mm3 in the United States, 159 cells/mm3 in Brazil
and 157 cells/mm3 in China [22].
Given the increasing consensus of the high D4T toxicity, crystallized in the WHO 2010 recommendations
[14], monitoring declines in D4T use is an important
objective of contemporary pharmaco-epidemiology. A
“gap” we observed is the marked differences in the use
of D4T and NVP over time and across countries with
similar economic resources. Although the fraction of
patients starting D4T-based regimens declined in all
countries, programmes in Uganda moved away from
D4T earlier and more extensively than those in Kenya
and Tanzania, and by 2009, included nearly 8% of regimens, which contained tenofovir.
The reasons for these differences, including the differences in healthcare systems and national policies, across
countries with similar economic resources available for
health require further explanation and research. In particular, interdisciplinary research focused on the economic, programmatic and policy issues that inform
national implementation programmes may yield further
explanations. Furthermore, the cost effectiveness of
these differences should be quantified: although countries using less D4T may have higher per patient costs
in the short run, the long-term quantification and prevention of morbidities associated with prolonged D4T
use must also be assessed.
Our analysis of factors associated with specific ART
drugs reflected, in general, rational drug choices and are
reassuring from a public health perspective. We found
several notable associations with D4T use. Male sex,
older age, higher pre-therapy CD4 counts and TB were
associated with a reduced risk of D4T use. Lower D4T
use in men and at higher CD4 count levels may be
explained by the lower prevalence of anaemia in men
and in healthier patients, and hence the absence of a
contraindication to zidovudine (AZT) use. Reduced D4T
use in patients with TB is potentially explained by the
desire to avoid the neurotoxic combination of isoniazid
and D4T [23]. The observed preponderance of efavirenz
(EFV) use in men likely reflects the desire to avoid EFV
in women who desire children, and the elevated use of
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EFV in those with TB reflects recognition of the interaction between NVP and rifampin [24,25].
A limitation of this manuscript is the cross-sectional
nature of the analyses. In cross-sectional studies, inferences must be made with care because time ordering is
not possible and selection bias is difficult to control. For
example, the finding that more men have advanced disease among patients accessing ART leads to the nominal
inference that the socio-behaviour characteristics of
HIV-infected men in east Africa prevents them from
seeking care. However, an alternative may be considered: if the distribution of advanced disease is similar in
men and women in the community (a plausible assumption especially early in the roll out when few patients
were accessing ART), then the observation that male
sex is associated with at advanced disease among
patients accessing ART could imply that female sex is
associated with advanced disease in patients unable to
access ART in the community.
A second limitation is that, although IeDEA spans
three countries, the patients from each country may not
be representative of the country as a whole in all
aspects. We believe, however, that sites are in general
prototypical ART scale-up clinics staffed and stocked by
national ministries of health and implementing partners
of the Global Fund and PEPFAR and should be fairly
representative of clinics in these countries. Third, the
data we analyzed were collected in the course of routine
clinical care, and the accuracy of certain measurements,
such as WHO staging, may be limited by few diagnostic
options. This may explain why a later calendar year was
associated with a slightly high proportion of patients
classified as WHO Stage 4 in Uganda even though the
CD4 count levels rose during that interval.

Conclusions
In summary, this study found encouraging trends over
time in east Africa where scale up of ART services has
expanded rapidly; however, gaps in effectiveness continue to exist. Patients are starting less toxic ART regimens, at clinics which are closer to their residences, free
of charge and at higher CD4 count levels. The improving characteristics at ART initiation can be expected to
have substantial effects on morbidity and mortality.
Areas that require further study and action include
evaluation of why men present with advanced disease
despite the fact that they control more resources in the
community. Although CD4 cell count levels at ART
initiation have risen, the average is still under 200 cells/
mm3, and continued monitoring is needed to document
further rises now that national guidelines have moved to
a threshold of 350 cells/mm3. D4T use remains too high
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and implementers must move towards systematic reduction of D4T use whenever possible.
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